257,779 Shares in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Purchased by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC purchased a new stake in ALX Oncology Holdings Inc. (NASDAQ:ALXO) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 257,779 shares of the company’s stock, valued at approximately $469,000. Los Angeles Capital Management LLC owned about 0.49% of ALX Oncology as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Swiss National Bank acquired a new position in shares of ALX Oncology in the first quarter valued at approximately $493,000. Vanguard Group Inc. grew its holdings in ALX Oncology by 4.3% in the 1st quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock valued at $17,466,000 after buying an additional 64,055 shares in the last quarter. CANADA LIFE ASSURANCE Co bought a new position in ALX Oncology during the 1st quarter worth $27,000. EntryPoint Capital LLC acquired a new stake in shares of ALX Oncology during the first quarter worth $32,000. Finally, Redmile Group LLC boosted its position in shares of ALX Oncology by 18.2% in the first quarter. Redmile Group LLC now owns 4,326,509 shares of the company’s stock valued at $48,241,000 after acquiring an additional 667,245 shares during the period. 97.97% of the stock is owned by institutional investors.

ALX Oncology Price Performance

Shares of NASDAQ:ALXO opened at $1.29 on Friday. ALX Oncology Holdings Inc. has a one year low of $1.25 and a one year high of $17.83. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. The company has a market cap of $68.04 million, a price-to-earnings ratio of -0.43 and a beta of 1.03. The firm has a 50 day simple moving average of $1.69 and a 200 day simple moving average of $5.49.

Analyst Upgrades and Downgrades

ALXO has been the subject of several analyst reports. Lifesci Capital cut shares of ALX Oncology from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 31st. UBS Group reduced their price target on ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, August 16th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a report on Tuesday, August 13th. Stifel Nicolaus reissued a “hold” rating and set a $3.00 target price (down from $5.00) on shares of ALX Oncology in a report on Friday, August 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research note on Tuesday, November 12th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $12.50.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.